NCT04541797View on ClinicalTrials.gov

Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)

NAActive, not recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

May 8, 2024

Study Completion Date

February 28, 2025

Conditions
Type 2 DiabetesMicrovascular Coronary Artery Disease
Interventions
DRUG

Empagliflozin 10 MG

Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.

DRUG

Placebo

Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).

DIAGNOSTIC_TEST

Stress Cardiac Magnetic Resonance

Imaging: All patients will have stress CMR examinations at recruitment.

Trial Locations (1)

Unknown

The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT04541797 - Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM) | Biotech Hunter | Biotech Hunter